bullish

Resapp Health

ResApp (RAP AU): Low-End Pfizer Offer As Cough Trial Fails

At A$0.12/share as I type, ResApp is trading at a very wide 21.6% gross spread. I'd take that bet. However, this is not a super liquid arb situation.

Event-Driven
393 Views, 21 Jun 2022 14:40
SUMMARY(Sign Up to Access)
The Smartkarma Preview Pass is your entry to the Independent Investment Research Network
  • Unlimited Research Summaries
  • Personalised Alerts
  • Custom Watchlists
  • Company Data & News
  • Events & Webinars
or
Trusted by:
Bloomberg
Societe Generale
SGX
Sequoia
Interactive Broker
Refinitiv
Already have an account? Sign In Now
Full Insight
(Paid Plans Only)
Discussions
(Paid Plans Only)
WHAT’S TRENDING
Insights
  • Trending
  • Latest
Logo
Top 5%
David Blennerhassett
Pan-Asia Catalysts/Events
Quiddity Advisors
EquitiesEvent-Driven
Price Chart(Sign Up to Access)
analytics-chart
  • ResApp (RAP AU): Pfizer Bumps Offer
    03 Aug 2022
  • ResApp (RAP AU): Low-End Pfizer Offer As Cough Trial Fails
    21 Jun 2022
  • ResApp (RAP AU): Pfizer Coughs Up
    15 Jun 2022
x